Category: Delcath Systems Inc.
Edwards Lifesciences said its CFO, Thomas Abate, plans to retire once a replacement is found later this year.
Edwards Lifesciences (NYSE:EW) said its finance chief, Thomas Abate, plans to retire later this year after a replacement is found.
The Irvine, Calif.-based medical device company said Abate, 60, will stay on as CFO while the search goes on. Edwards hired Peter Crist of Crist/Kolder Associates to assist in the quest, according to a press release.
An FDA advisory panel unanimously recommends against approval for Delcath's liver cancer treatment, citing a too-high mortality rate, slashing nearly half the value from the company's stock.
Shares of Delcath (NSDQ:DCTH) have lost nearly half their value so far today after an FDA panel recommended against approval for its liver cancer treatment.
Shares of Delcath rise 8% after the German government puts reimbursement in place for its Chemosat device for treating liver cancer.
Delcath (NSDQ:DCTH) shares gained 8% today after the German government decided to reimburse patients who receive the medical device company's Chemosat liver cancer treatment.
Medical device company Delcath Systems lands Australian approval for its cancer-treatment system, and lands a definitive date with the FDA to review the device under a New Drug Application.
Medical device company Delcath Systems (NSDQ:DCTH) is on a roll, notching a couple new regulatory milestones this month for its organ-isolating ChemoSat chemotherapy treatment systems.
Delcath lands expanded CE Mark approval in the European Union to market its targeted chemotherapy delivery system with a drug commonly used to destroy liver tumors.
Delcath Systems (NSDQ:DCTH) won expanded CE Mark approval in the European Union for its ChemoSat organ-isolating cancer treatment system, landing indication for a new drug used to target liver tumors.
The FDA accepts for review Delcath's 2nd new drug application, bringing the device maker one step closer to launching its ChemoSat drug-device combination on the U.S. market.
The FDA agreed to review Delcath Systems' (NSDQ:DCTH) new drug application, bringing the device maker 1 step closer to launching its organ-isolating chemotherapy system on the U.S. market.
Delcath files its 2nd new drug application in hopes of gaining FDA approval for the ChemoSat Generation 2 chemotherapy isolation system.
Delcath Systems (NSDQ:DCTH) filed a new FDA application for the latest iteration of its ChemoSat drug-device combination, the Generation 2 device, in treatment of patients with non-operable liver cancer.
